Trial Outcomes & Findings for Safety and Performance Study of the FAST-FIX FLEX System for Meniscal Repairs and Meniscal Transplantations (NCT NCT04903106)
NCT ID: NCT04903106
Last Updated: 2026-03-18
Results Overview
Count of participants with reoperations due to meniscal repair failure at 12 months postoperative. Failure was defined as revision surgery at the primary site of the tear.
COMPLETED
63 participants
12 months
2026-03-18
Participant Flow
Participant milestones
| Measure |
Meniscal Repair (MR)
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Overall Study
STARTED
|
53
|
10
|
|
Overall Study
COMPLETED
|
47
|
10
|
|
Overall Study
NOT COMPLETED
|
6
|
0
|
Reasons for withdrawal
| Measure |
Meniscal Repair (MR)
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Overall Study
Adverse Event
|
1
|
0
|
|
Overall Study
Lost to Follow-up
|
5
|
0
|
Baseline Characteristics
Safety and Performance Study of the FAST-FIX FLEX System for Meniscal Repairs and Meniscal Transplantations
Baseline characteristics by cohort
| Measure |
Meniscal Repair (MR)
n=53 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
Total
n=63 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
32.0 years
STANDARD_DEVIATION 11.5 • n=110 Participants
|
29.4 years
STANDARD_DEVIATION 5.6 • n=114 Participants
|
31.6 years
STANDARD_DEVIATION 10.8 • n=224 Participants
|
|
Sex: Female, Male
Female
|
16 Participants
n=110 Participants
|
6 Participants
n=114 Participants
|
22 Participants
n=224 Participants
|
|
Sex: Female, Male
Male
|
37 Participants
n=110 Participants
|
4 Participants
n=114 Participants
|
41 Participants
n=224 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
5 Participants
n=110 Participants
|
1 Participants
n=114 Participants
|
6 Participants
n=224 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
41 Participants
n=110 Participants
|
8 Participants
n=114 Participants
|
49 Participants
n=224 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
7 Participants
n=110 Participants
|
1 Participants
n=114 Participants
|
8 Participants
n=224 Participants
|
|
Body Mass Index (BMI)
|
24.9 kg/m^2
STANDARD_DEVIATION 3.1 • n=110 Participants
|
27.6 kg/m^2
STANDARD_DEVIATION 3.0 • n=114 Participants
|
25.3 kg/m^2
STANDARD_DEVIATION 3.2 • n=224 Participants
|
PRIMARY outcome
Timeframe: 12 monthsPopulation: Safety Population (SAF) included all participants treated with the FAST-FIX FLEX study device with data collected for this outcome at the indicated time frame.
Count of participants with reoperations due to meniscal repair failure at 12 months postoperative. Failure was defined as revision surgery at the primary site of the tear.
Outcome measures
| Measure |
Meniscal Repair (MR)
n=53 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Reoperations at 12 Months
|
3 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: Safety Population (SAF) included all participants treated with the FAST-FIX FLEX study device with data collected for this outcome at the indicated time frame.
Count of participants with reoperations due to meniscal repair failure at 6 months postoperative. Failure was defined as revision surgery at the primary site of the tear.
Outcome measures
| Measure |
Meniscal Repair (MR)
n=53 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Reoperations at 6 Months
|
1 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Month 6 to Month 12, approximately 6 monthsPopulation: Safety Population (SAF) included all participants treated with the study device that had data collected for this outcome at the indicated time frame. Two participants in the Meniscal Repair group are excluded due to withdrawal from the study prior to the start of the Month 6 period.
Count of participants with reoperations due to meniscal repair failure during the period starting from Month 6 postoperatively (227 days after surgery) to Month 12 postoperatively. Failure was defined as a revision of the transplantation and/or removal of the allograft.
Outcome measures
| Measure |
Meniscal Repair (MR)
n=49 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Reoperations From Month 6 to Month 12
|
2 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 6 months and 12 monthsPopulation: Full Analysis Set (FAS) population followed the intention-to-treat principle that included all participants recruited into the study that attended at least one post-surgery assessment with data collected for this outcome at the indicated time frame.
MRI to assess number of participants with structural integrity and meniscal healing at 6 months and 12 months was derived by the meniscal repair status according to one the following categories: * Grade 0 - Low signal intensity at the site of original tear(s). * Grade 1 - Irregularly marginated, elevated signal with globular shape, at the site of original tear(s). * Grade 2 - Linear elevated signal (i.e. confirmed fluid signal) at the site of original tear(s), not extending into the tibial or femoral articular surface. * Grade 3 - Linear elevated signal (i.e. confirmed fluid signal) at the site of original tear(s), extending into the tibial or femoral articular surface, suggestive of a re-tear. * UA - Unable to Assess * NR - Not Required
Outcome measures
| Measure |
Meniscal Repair (MR)
n=48 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=9 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Meniscal Healing by Meniscal Repair Status Grading
6 months · Grade 0
|
3 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
6 months · Grade 1
|
13 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
6 months · Grade 2
|
9 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
6 months · Grade 3
|
22 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
6 months · UA (Unable to assess)
|
1 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
6 months · NR (Not required)
|
0 Participants
|
9 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
12 months · Grade 0
|
2 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
12 months · Grade 1
|
18 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
12 months · Grade 2
|
9 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
12 months · Grade 3
|
14 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
12 months · UA (Unable to assess)
|
0 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Repair Status Grading
12 months · NR (Not required)
|
0 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: 6 months and 12 monthsPopulation: Full Analysis Set (FAS) population followed the intention-to-treat principle that included all participants recruited into the study that attended at least one post-surgery assessment with data collected for this outcome at the indicated time frame.
MRI to assess number of participants with structural integrity and meniscal healing at 6 months and 12 months for meniscal transplant status was derived from relative percentage of extrusion (RPE) recorded on the coronal plane and sagittal plane using the following categories: * Grade 0 - RPE \< 50% on both sagittal and coronal planes, i.e. RPE (Radial) \< 50% AND \[RPE (Anterior) \< 50% AND RPE (Posterior) \< 50%\]. * Grade 1 - RPE ≥ 50% on only one plane, i.e. RPE (Radial) ≥ 50% OR \[RPE (Anterior) ≥ 50% OR RPE (Posterior) ≥ 50%\]. * Grade 2 - RPE ≥ 50% on both sagittal and coronal planes, i.e. RPE (Radial) ≥ 50% AND \[RPE (Anterior) ≥ 50% OR RPE (Posterior) ≥ 50%\]. * NR - Not Required
Outcome measures
| Measure |
Meniscal Repair (MR)
n=48 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=9 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Meniscal Healing by Meniscal Transplant Status Grading
6 months · Grade 0
|
0 Participants
|
4 Participants
|
|
Meniscal Healing by Meniscal Transplant Status Grading
6 months · Grade 1
|
0 Participants
|
5 Participants
|
|
Meniscal Healing by Meniscal Transplant Status Grading
6 months · Grade 2
|
0 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Transplant Status Grading
6 months · NR (Not required)
|
48 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Transplant Status Grading
12 months · Grade 0
|
0 Participants
|
6 Participants
|
|
Meniscal Healing by Meniscal Transplant Status Grading
12 months · Grade 1
|
0 Participants
|
3 Participants
|
|
Meniscal Healing by Meniscal Transplant Status Grading
12 months · Grade 2
|
0 Participants
|
0 Participants
|
|
Meniscal Healing by Meniscal Transplant Status Grading
12 months · NR (Not required)
|
43 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Pre-operatively, 6 months and 12 monthsPopulation: Full Analysis Set (FAS) population followed the intention-to-treat principle that included all participants recruited into the study that attended at least one post-surgery assessment with data collected for this outcome at the indicated time frame.
The International Knee Documentation Committee (IKDC) Subjective score was developed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment, including patients with meniscal injuries. Possible scores range from 0-100, where 100 indicated the highest level of function and lowest level of symptoms (i.e., better outcome), and 0 indicated the lowest level of function or highest level of symptoms (i.e., worse outcome).
Outcome measures
| Measure |
Meniscal Repair (MR)
n=53 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Patient Reported Outcome (PRO): International Knee Documentation Committee (IKDC) Subjective Score
Baseline
|
59.0 score on a scale
Standard Deviation 13.4
|
66.3 score on a scale
Standard Deviation 8.8
|
|
Patient Reported Outcome (PRO): International Knee Documentation Committee (IKDC) Subjective Score
6 months
|
72.5 score on a scale
Standard Deviation 9.1
|
61.3 score on a scale
Standard Deviation 13.3
|
|
Patient Reported Outcome (PRO): International Knee Documentation Committee (IKDC) Subjective Score
12 months
|
75.7 score on a scale
Standard Deviation 11.5
|
71.4 score on a scale
Standard Deviation 14.2
|
SECONDARY outcome
Timeframe: Pre-operatively, 6 months and 12 monthsPopulation: Full Analysis Set (FAS) population followed the intention-to-treat principle that included all participants recruited into the study that attended at least one post-surgery assessment with data collected for this outcome at the indicated time frame.
The Lysholm Knee Scoring Scale measures the participant's symptoms and functioning of daily activities by assessing 8 items: limping, using cane or crutches, locking sensation in the knee, giving way sensation from the knee, pain, swelling, climbing stairs, and squatting. The scores are on a scale from 0 to 100, with a higher score indicating fewer symptoms and a higher level of functioning (i.e., a better outcome).
Outcome measures
| Measure |
Meniscal Repair (MR)
n=53 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Patient Reported Outcome (PRO): Lysholm Score
Baseline
|
60.3 score on a scale
Standard Deviation 22.0
|
73.2 score on a scale
Standard Deviation 16.3
|
|
Patient Reported Outcome (PRO): Lysholm Score
6 months
|
87.3 score on a scale
Standard Deviation 12.0
|
75.8 score on a scale
Standard Deviation 21.4
|
|
Patient Reported Outcome (PRO): Lysholm Score
12 months
|
87.5 score on a scale
Standard Deviation 14.0
|
87.2 score on a scale
Standard Deviation 12.7
|
SECONDARY outcome
Timeframe: Pre-operatively, 6 months and 12 monthsPopulation: Full Analysis Set (FAS) population followed the intention-to-treat principle that included all participants recruited into the study that attended at least one post-surgery assessment with data collected for this outcome at the indicated time frame.
The EQ-5D-5L is composed of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The EQ VAS score is on a scale of 0 to 100 with 0 indicating 'the worst health you can imagine' and 100 indicating 'the best health you can imagine' (i.e., a higher score is a better outcome).
Outcome measures
| Measure |
Meniscal Repair (MR)
n=53 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Patient Reported Outcome (PRO): EuroQol 5 Dimension 5 Level (EQ-5D-5L): Visal Analogue Scale (VAS) Score
Baseline
|
78.47 score on a scale
Standard Deviation 13.16
|
72.0 score on a scale
Standard Deviation 19.18
|
|
Patient Reported Outcome (PRO): EuroQol 5 Dimension 5 Level (EQ-5D-5L): Visal Analogue Scale (VAS) Score
6 months
|
83.22 score on a scale
Standard Deviation 11.08
|
83.0 score on a scale
Standard Deviation 10.33
|
|
Patient Reported Outcome (PRO): EuroQol 5 Dimension 5 Level (EQ-5D-5L): Visal Analogue Scale (VAS) Score
12 months
|
84.70 score on a scale
Standard Deviation 12.83
|
81.4 score on a scale
Standard Deviation 11.14
|
SECONDARY outcome
Timeframe: Pre-operatively, 6 months and 12 monthsPopulation: Full Analysis Set (FAS) population followed the intention-to-treat principle that included all participants recruited into the study that attended at least one post-surgery assessment with data collected for this outcome at the indicated time frame.
The EQ-5D-5L is composed of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression) to create a combined Health Score. The combined Health Score is on a scale of 0 to 1 with a higher score indicating a better outcome.
Outcome measures
| Measure |
Meniscal Repair (MR)
n=53 Participants
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 Participants
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Patient Reported Outcome (PRO): EuroQol 5 Dimension 5 Level (EQ-5D-5L): Health Score
Baseline
|
0.74 score on a scale
Standard Deviation 0.18
|
0.68 score on a scale
Standard Deviation 0.15
|
|
Patient Reported Outcome (PRO): EuroQol 5 Dimension 5 Level (EQ-5D-5L): Health Score
6 months
|
0.87 score on a scale
Standard Deviation 0.11
|
0.81 score on a scale
Standard Deviation 0.16
|
|
Patient Reported Outcome (PRO): EuroQol 5 Dimension 5 Level (EQ-5D-5L): Health Score
12 months
|
0.90 score on a scale
Standard Deviation 0.11
|
0.86 score on a scale
Standard Deviation 0.11
|
Adverse Events
Meniscal Repair (MR)
Meniscal Allograft Transplant (MAT)
Serious adverse events
| Measure |
Meniscal Repair (MR)
n=53 participants at risk
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 participants at risk
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Psychiatric disorders
EMOTIONAL CHANGES
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Immune system disorders
LOCAL REACTION
|
0.00%
0/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
10.0%
1/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Cardiac disorders
NON SPECIFIC EKG/ECG CHANGES
|
0.00%
0/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
10.0%
1/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Musculoskeletal and connective tissue disorders
DAMAGE TO LIGAMENT(S)
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Musculoskeletal and connective tissue disorders
LOSS OF RANGE OF MOTION
|
3.8%
2/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Infections and infestations
PNEUMONIA
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Injury, poisoning and procedural complications
EROSION
|
0.00%
0/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
10.0%
1/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Injury, poisoning and procedural complications
FALL
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Injury, poisoning and procedural complications
FAILURE OF IMPLANT
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Injury, poisoning and procedural complications
POST OPERATIVE WOUND INFECTION
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
General disorders
PAIN
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
Other adverse events
| Measure |
Meniscal Repair (MR)
n=53 participants at risk
Participant required a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
|
Meniscal Allograft Transplant (MAT)
n=10 participants at risk
Participant required a Meniscal Allograft Transplant (MAT) for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
|
|---|---|---|
|
Injury, poisoning and procedural complications
DAMAGE TO LIGAMENT(S)
|
3.8%
2/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Musculoskeletal and connective tissue disorders
JOINT LAXITY
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Musculoskeletal and connective tissue disorders
LOSS OF RANGE OF MOTION
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Musculoskeletal and connective tissue disorders
MUSCLE/TENDON DAMAGE
|
3.8%
2/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Musculoskeletal and connective tissue disorders
SYNOVITIS
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Nervous system disorders
CONVULSION/SEIZURE
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Nervous system disorders
PERIPHERAL NERVOUS INJURY
|
0.00%
0/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
20.0%
2/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Cardiac disorders
TACHYCARDIA
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
0.00%
0/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Skin and subcutaneous tissue disorders
SCAR TISSUE
|
1.9%
1/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
10.0%
1/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
Injury, poisoning and procedural complications
FALL
|
3.8%
2/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
10.0%
1/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
General disorders
PAIN
|
9.4%
5/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
20.0%
2/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
General disorders
SWELLING/ EDEMA
|
5.7%
3/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
20.0%
2/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
|
General disorders
INSUFFICIENT INFORMATION
|
0.00%
0/53 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
10.0%
1/10 • Adverse events were collected from surgery through study completion or termination, approximately 13 months
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60